Andrew Chung, M.D., Ph.D.

(877) 460-4673
Andrew Chung, M.D., Ph.D.
Nocturnist
Clinical Expertise
  • Hospital Medicine
  • Internal Medicine
  • Inpatient Oncology Care
  • Nocturnist Medicine
  • Complex Medical Conditions
Research Area
  • Triple negative breast cancer
  • Chemotherapy resistance
  • Immune-mediated disease pathogenesis
  • Leprosy
  • Vitiligo
  • Melanoma
Academic Appointments

Assistant Clinical Professor, Division of Hospital Medicine, Department of Medicine

Clinical Teams
Hospital Medicine

Andrew Chung, M.D., Ph.D., is a nocturnist and assistant clinical professor in the Division of Hospital Medicine, Department of Medicine, at City of Hope® Cancer Center Duarte. He provides inpatient care for hospitalized patients and helps manage complex medical conditions that arise during cancer treatment. 
Dr. Chung earned his M.D. and Ph.D. from Texas A&M Health Science Center College of Medicine and completed his internal medicine residency at Houston Methodist Hospital in Houston, Texas.
Prior to his clinical training, Dr. Chung conducted research focused on cancer therapeutics, tumor biology and the human immune system. He has authored peer-reviewed publications in journals including Science Translational Medicine, npj Breast Cancer and The Journal of Infectious Diseases.
A native Los Angeleno, Dr. Chung was drawn to City of Hope because of its leadership in cancer research and patient care. He is committed to providing compassionate, patient-centered care and partnering with patients and families through challenging diagnoses and treatments.

Location

Education & Experience

Degrees

  • 2023, Doctor of Medicine, Texas A&M Health Science Center College of Medicine, College Station, TX
  • 2023, Doctor of Philosophy, Texas A&M Health Science Center, College Station, TX
  • 2009, Bachelor of Arts, Molecular Cell Biology, University of California, Berkeley, Berkeley, CA

Residency

  • 2026, Internal Medicine, Houston Methodist Hospital, Houston, TX

Professional Experience

  • 2026-present, Assistant Clinical Professor, Division of Hospital Medicine, Department of Medicine, City of Hope, Duarte, CA

Research

  • Projects investigating chemo-resistant mechanisms of triple negative breast cancer.
  • Investigated immune-mediated pathways in disease pathogenesis and resistance mechanisms in leprosy and vitiligo.
  • Pursued studies investigating immunoregulatory mechanisms in leprosy and melanoma.

Publications

  • Chung AW, Sieling PA, Schenk M, et al. Galectin-3 regulates the innate immune response of human monocytes. The Journal of Infectious Diseases. 2013.
  • Chung AW, Anand K, Anselme AC, et al. A phase 1/2 clinical trial of an inducible nitric oxide synthase inhibitor and taxane for treating chemoresistant triple-negative breast cancer. Science Translational Medicine. 2021.
  • Chung AW, Kozielski AJ, Qian W, et al. Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6. npj Breast Cancer. 2022.